Processa Pharmaceuticals, Inc.

corporate_fare Company Profile

Processa Pharmaceuticals, Inc.

PCSA·NASDAQ·Healthcare·CIK 0001533743

Processa Pharmaceuticals, Inc. is a publicly listed clinical-stage biopharmaceutical company incorporated in Delaware on March 29, 2011. The company focuses on developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Their strategy involves identifying existing cancer therapies with well-understood mechanisms of action that are cornerstones of current treatment regimens but are highly toxic with treatment-limiting side effects. Processa then devises technologies to alter how the body metabolizes or distributes these therapies to enhance their therapeutic effect and reduce toxicity. The company develops its NGC therapies using its proprietary Regulatory Science Approach. Currently, one NGC small molecule is in a Phase 2 trial, while another is in pre-clinical development.

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is a publicly traded company in the Healthcare sector. Wiseek monitors PCSA SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

Processa Pharmaceuticals Issues Going Concern Warning Amidst Significant Cash Burn and Urgent Capital Needs (2026-05-07)
Processa Pharmaceuticals Amends 10-K to Detail $1.4M Capital Raises and Executive Compensation (2026-04-30)
Chief Development Officer Transitions to Part-Time Role, No Longer Executive Officer (2026-04-30)
Major Investor Increases Stake in Processa Pharmaceuticals with $200K Purchase (2026-02-23)
Processa Pharmaceuticals' PCS12852 Licensing Agreement with Intact Therapeutics Terminates (2026-02-19)

Financial Snapshot

Fiscal year ended December 31, 2025

Net Income

-$13.56M

Diluted EPS

-$10.36

Op. Cash Flow

-$11.39M

Operating Income

-$13.99M

Cash & Equivalents

$5.54M

Debt / Equity

0.00×

Shares Outstanding

2.57M sh

Source: 10-K · filed 2026-04-30 · accession 0001493152-26-020731

Browse all tickers starting with P →

show_chartPrice Chart

Loading chart...

feed PCSA - Latest Insights

Filing Type

Date Range

PCSA

May 07, 2026, 4:18 PM EDT

Filing Type: 10-Q

Importance Score:

Processa Pharmaceuticals Issues Going Concern Warning Amidst Significant Cash Burn and Urgent Capital Needs

Price at Filing: $2.87

Real-time Price: $2.17

Change: -$0.700 (-24%)

Market Cap: $5.968M

Sentiment: Negative

View Wiseek Article

PCSA

Apr 30, 2026, 5:14 PM EDT

Filing Type: 10-K/A

Importance Score:

Processa Pharmaceuticals Amends 10-K to Detail $1.4M Capital Raises and Executive Compensation

Price at Filing: $2.70

Real-time Price: $2.17

Change: -$0.530 (-20%)

Market Cap: $5.968M

Sentiment: Neutral

View Wiseek Article

PCSA

Apr 30, 2026, 5:11 PM EDT

Filing Type: 8-K

Importance Score:

Chief Development Officer Transitions to Part-Time Role, No Longer Executive Officer

Price at Filing: $2.70

Real-time Price: $2.17

Change: -$0.530 (-20%)

Market Cap: $5.968M

Sentiment: Neutral

View Wiseek Article

PCSA

Feb 23, 2026, 11:00 AM EST

Filing Type: SCHEDULE 13D/A

Importance Score:

Major Investor Increases Stake in Processa Pharmaceuticals with $200K Purchase

Price at Filing: $2.09

Real-time Price: $2.17

Change: +$0.0833 (+4%)

Market Cap: $5.968M

Sentiment: Positive

View Wiseek Article

PCSA

Feb 19, 2026, 4:05 PM EST

Filing Type: 8-K

Importance Score:

Processa Pharmaceuticals' PCS12852 Licensing Agreement with Intact Therapeutics Terminates

Price at Filing: $2.28

Real-time Price: $2.17

Change: -$0.110 (-5%)

Market Cap: $5.968M

Sentiment: Negative

View Wiseek Article

PCSA

Jan 07, 2026, 8:30 AM EST

Filing Type: 8-K

Importance Score:

Processa Pharmaceuticals Regains Nasdaq Compliance, Averting Delisting Threat

Price at Filing: $3.58

Real-time Price: $2.17

Change: -$1.41 (-39%)

Market Cap: $5.968M

Sentiment: Positive

View Wiseek Article

corporate_fare Company Profile